Follicular Lymphoma - Pipeline Review, H2 2015

Date: December 23, 2015
Pages: 478
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: FB02B6A16FAEN
Leaflet:

Download PDF Leaflet

Follicular Lymphoma - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Follicular Lymphoma - Pipeline Review, H2 2015’, provides an overview of the Follicular Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Follicular Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Follicular Lymphoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Follicular Lymphoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Follicular Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Follicular Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Follicular Lymphoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Follicular Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Follicular Lymphoma Overview
Therapeutics Development
Pipeline Products for Follicular Lymphoma - Overview
Pipeline Products for Follicular Lymphoma - Comparative Analysis
Follicular Lymphoma - Therapeutics under Development by Companies
Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes
Follicular Lymphoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Follicular Lymphoma - Products under Development by Companies
Follicular Lymphoma - Products under Investigation by Universities/Institutes
Follicular Lymphoma - Companies Involved in Therapeutics Development
AbbVie Inc.
Affimed Therapeutics AG
AmpliMed Corporation (Inactive)
Bayer AG
BeiGene(Beijing) Co.,Ltd
Bio-Path Holdings, Inc.
Biocon Limited
Biogenomics Limited
Biothera, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Celltrion, Inc.
Cellular Biomedicine Group, Inc.
Coherus BioSciences, Inc.
CTI BioPharma Corp.
Curis, Inc.
Dynavax Technologies Corporation
Eisai Co., Ltd.
EpiZyme, Inc.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Hutchison MediPharma Limited
ImmunoGen, Inc.
Immunomedics, Inc.
Infinity Pharmaceuticals, Inc.
Johnson & Johnson
Karyopharm Therapeutics, Inc.
Kite Pharma, Inc.
Les Laboratoires Servier SAS
MedImmune, LLC
Medivation, Inc.
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
MorphoSys AG
Nordic Nanovector ASA
Novartis AG
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Pharmacyclics, Inc.
Portola Pharmaceuticals, Inc.
ProNAi Therapeutics, Inc.
Sandoz International GmbH
Seattle Genetics, Inc.
TG Therapeutics, Inc.
Follicular Lymphoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abexinostat hydrochloride - Drug Profile
acalabrutinib - Drug Profile
AFM-11 - Drug Profile
alisertib - Drug Profile
ASN-002 - Drug Profile
atezolizumab - Drug Profile
azacitidine - Drug Profile
Betalutin - Drug Profile
BGB-3111 - Drug Profile
bortezomib - Drug Profile
BP-100102 - Drug Profile
buparlisib hydrochloride - Drug Profile
BVX-20 - Drug Profile
CBM-C19.1 - Drug Profile
CBM-C20.1 - Drug Profile
Cellular Immunotherapy to Target CD22 for B-Cell Leukemia and Lymphoma - Drug Profile
Cellular Immunotherapy to Target GM-CSF for Oncology - Drug Profile
cerdulatinib - Drug Profile
copanlisib hydrochloride - Drug Profile
CUDC-907 - Drug Profile
daratumumab - Drug Profile
dasiprotimut-T - Drug Profile
denintuzumab mafodotin - Drug Profile
duvelisib - Drug Profile
E-7449 - Drug Profile
entospletinib - Drug Profile
epratuzumab - Drug Profile
GS-9901 - Drug Profile
GSK-2816126 - Drug Profile
HMPL-523 - Drug Profile
ibrutinib - Drug Profile
ibrutinib + ublituximab + TGR-1202 - Drug Profile
idelalisib - Drug Profile
IGN-002 - Drug Profile
imexon - Drug Profile
IMGN-529 - Drug Profile
IMMU-114 - Drug Profile
Imprime PGG - Drug Profile
inebilizumab - Drug Profile
inebilizumab + MEDI-0680 - Drug Profile
inebilizumab + rituximab - Drug Profile
interferon alfa-2b - Drug Profile
interferon alfa-2b - Drug Profile
ixazomib citrate - Drug Profile
JNJ-64052781 - Drug Profile
KTEC-19 - Drug Profile
lenalidomide - Drug Profile
mocetinostat - Drug Profile
Monoclonal Antibody Conjugated to Target CD22 for Hematological Cancers - Drug Profile
MOR-208 - Drug Profile
nivolumab - Drug Profile
obinutuzumab - Drug Profile
Oncoquest - Drug Profile
pembrolizumab - Drug Profile
pidilizumab - Drug Profile
pixantrone dimaleate - Drug Profile
PNT-2258 - Drug Profile
polatuzumab vedotin - Drug Profile
rituximab biosimilar - Drug Profile
rituximab biosimilar - Drug Profile
rituximab biosimilar - Drug Profile
rituximab biosimilar - Drug Profile
rituximab biosimilar - Drug Profile
rituximab biosimilar - Drug Profile
rituximab biosimilar - Drug Profile
S-055746 - Drug Profile
SD-101 - Drug Profile
selinexor - Drug Profile
SGN-CD70A - Drug Profile
SH-7129 - Drug Profile
tazemetostat - Drug Profile
temsirolimus - Drug Profile
TGR-1202 - Drug Profile
tisagenlecleucel-T - Drug Profile
ublituximab + TGR-1202 - Drug Profile
ulocuplumab - Drug Profile
urelumab - Drug Profile
Vaccine for Follicular Lymphoma - Drug Profile
Vaccine for Multiple Myeloma and Follicular Lymphoma - Drug Profile
venetoclax - Drug Profile
vorinostat - Drug Profile
Follicular Lymphoma - Recent Pipeline Updates
Follicular Lymphoma - Dormant Projects
Follicular Lymphoma - Discontinued Products
Follicular Lymphoma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Follicular Lymphoma, H2 2015
Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Investigation by Universities/Institutes, H2 2015
Follicular Lymphoma - Pipeline by AbbVie Inc., H2 2015
Follicular Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2015
Follicular Lymphoma - Pipeline by AmpliMed Corporation (Inactive), H2 2015
Follicular Lymphoma - Pipeline by Bayer AG, H2 2015
Follicular Lymphoma - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015
Follicular Lymphoma - Pipeline by Bio-Path Holdings, Inc., H2 2015
Follicular Lymphoma - Pipeline by Biocon Limited, H2 2015
Follicular Lymphoma - Pipeline by Biogenomics Limited, H2 2015
Follicular Lymphoma - Pipeline by Biothera, Inc., H2 2015
Follicular Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Follicular Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2015
Follicular Lymphoma - Pipeline by Celgene Corporation, H2 2015
Follicular Lymphoma - Pipeline by Celltrion, Inc., H2 2015
Follicular Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2015
Follicular Lymphoma - Pipeline by Coherus BioSciences, Inc., H2 2015
Follicular Lymphoma - Pipeline by CTI BioPharma Corp., H2 2015
Follicular Lymphoma - Pipeline by Curis, Inc., H2 2015
Follicular Lymphoma - Pipeline by Dynavax Technologies Corporation, H2 2015
Follicular Lymphoma - Pipeline by Eisai Co., Ltd., H2 2015
Follicular Lymphoma - Pipeline by EpiZyme, Inc., H2 2015
Follicular Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Follicular Lymphoma - Pipeline by Genentech, Inc., H2 2015
Follicular Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2015
Follicular Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2015
Follicular Lymphoma - Pipeline by Hutchison MediPharma Limited, H2 2015
Follicular Lymphoma - Pipeline by ImmunoGen, Inc., H2 2015
Follicular Lymphoma - Pipeline by Immunomedics, Inc., H2 2015
Follicular Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015
Follicular Lymphoma - Pipeline by Johnson & Johnson, H2 2015
Follicular Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Follicular Lymphoma - Pipeline by Kite Pharma, Inc., H2 2015
Follicular Lymphoma - Pipeline by Les Laboratoires Servier SAS, H2 2015
Follicular Lymphoma - Pipeline by MedImmune, LLC, H2 2015
Follicular Lymphoma - Pipeline by Medivation, Inc., H2 2015
Follicular Lymphoma - Pipeline by Merck & Co., Inc., H2 2015
Follicular Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Follicular Lymphoma - Pipeline by Mirati Therapeutics Inc., H2 2015
Follicular Lymphoma - Pipeline by MorphoSys AG, H2 2015
Follicular Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2015
Follicular Lymphoma - Pipeline by Novartis AG, H2 2015
Follicular Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Follicular Lymphoma - Pipeline by Pfizer Inc., H2 2015
Follicular Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2015
Follicular Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2015
Follicular Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H2 2015
Follicular Lymphoma - Pipeline by Sandoz International GmbH, H2 2015
Follicular Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2015
Follicular Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Follicular Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015
Follicular Lymphoma - Dormant Projects, H2 2015
Follicular Lymphoma - Dormant Projects (Contd..1), H2 2015
Follicular Lymphoma - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Follicular Lymphoma, H2 2015
Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

COMPANIES MENTIONED

AbbVie Inc.
Affimed Therapeutics AG
AmpliMed Corporation (Inactive)
Bayer AG
BeiGene(Beijing) Co.,Ltd
Bio-Path Holdings, Inc.
Biocon Limited
Biogenomics Limited
Biothera, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Celltrion, Inc.
Cellular Biomedicine Group, Inc.
Coherus BioSciences, Inc.
CTI BioPharma Corp.
Curis, Inc.
Dynavax Technologies Corporation
Eisai Co., Ltd.
EpiZyme, Inc.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Hutchison MediPharma Limited
ImmunoGen, Inc.
Immunomedics, Inc.
Infinity Pharmaceuticals, Inc.
Johnson & Johnson
Karyopharm Therapeutics, Inc.
Kite Pharma, Inc.
Les Laboratoires Servier SAS
MedImmune, LLC
Medivation, Inc.
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
MorphoSys AG
Nordic Nanovector ASA
Novartis AG
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Pharmacyclics, Inc.
Portola Pharmaceuticals, Inc.
ProNAi Therapeutics, Inc.
Sandoz International GmbH
Seattle Genetics, Inc.
TG Therapeutics, Inc.
Skip to top


Burkitt Lymphoma - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 124 pages
Mantle Cell Lymphoma - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 426 pages
Acute Lymphoblastic Lymphoma - Pipeline Review, H2 2015 US$ 1,600.00 Sep, 2015 · 45 pages
T-Cell Lymphomas - Pipeline Review, H1 2014 US$ 1,500.00 Apr, 2014 · 132 pages
Burkitt Lymphoma - Pipeline Review, H1 2016 US$ 2,000.00 May, 2016 · 115 pages

Ask Your Question

Follicular Lymphoma - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: